Laserfiche WebLink
<br />E-1 <br /> <br /> <br />EXHIBIT E <br /> <br />Template Consent Judgment <br /> <br /> <br />[CASE] <br /> <br />[COURT] <br /> C.A. NO.: <br /> <br /> <br /> <br />FINAL CONSENT JUDGMENT AND DISMISSAL WITH PREJUDICE <br /> <br />The State of Washington (“State”) and Johnson & Johnson, Johnson & Johnson Innovative <br />Medicine, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen <br />Pharmaceutica, Inc. (collectively, “Janssen” or “Defendants”) (together with the State, the <br />“Parties,” and each a “Party”) have entered into a consensual resolution of the above-captioned <br />litigation (the “Action”) pursuant to a settlement agreement entitled Janssen Washington State-Wide <br />Opioid Settlement Agreement, dated as of January 22, 2024 (the “Agreement”), a copy of which is <br />attached hereto as Exhibit A. The entry of this Final Consent Judgment (the “Judgment”) by the <br />Court is made without trial or adjudication of any contested issue of fact or law, and without finding <br />or admission of wrongdoing or liability of any kind. <br />RECITALS: <br />1. Each Party warrants and represents that it engaged in arm’s-length negotiations in <br />good faith. In hereby executing the Agreement, the Parties intend to effect a good-faith settlement. <br />2. The State has determined that the Agreement is in the public interest. <br />3. Janssen denies the allegations against it and that it has any liability whatsoever to the <br />State, its Subdivisions, and/or (a) any of the State’s or Subdivisions’ departments, agencies, divisions,